Forte Biosciences (FBRX) Q4 2018 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2018 earnings summary
10 Nov, 2026Executive summary
Lead program Toca 511 & Toca FC remained in a pivotal Phase 3 trial for recurrent high-grade glioma, with 380-patient enrollment completed in September 2018.
First interim analysis recommended continuing Toca 5 without modification; the next interim analysis and final analysis were planned for 2019.
Financial highlights
FY2018 license revenue was $18.0M, primarily the $16.0M ApolloBio upfront payment and a $2.0M enrollment milestone; FY2017 revenue was $41K.
FY2018 R&D expense rose to $51.1M from $29.1M, mainly on higher Phase 3 manufacturing and trial costs; G&A increased to $12.8M from $8.6M.
FY2018 operating loss was $45.9M and net loss was $49.0M, versus $37.6M and $38.9M, respectively, in FY2017; basic and diluted loss per share was $2.44.
Cash, cash equivalents and marketable securities totaled $96.1M at Dec. 31, 2018, versus $88.7M a year earlier; working capital was $81.2M.
Outlook and guidance
Year-end liquidity was expected to fund operations for at least 12 months, though further capital was expected to be needed for ongoing development and commercialization.
Toca 5’s second interim analysis was planned for 1H 2019 and final analysis for 4Q 2019, contingent on reaching the specified event thresholds.
The NRG Oncology Phase 2/3 trial in newly diagnosed glioblastoma was expected to begin by the end of 2019; planned work included safety and preliminary efficacy evaluation with standard treatments.
Latest events from Forte Biosciences
- Entered merger agreement with argenx for $77/share; $198.5M cash; FB102 trials advance.FBRX
Q2 2026 - FB102 shows strong efficacy and safety in celiac disease, with broad potential in autoimmune therapy.FBRX
Corporate presentation - FB102 produced significant, durable repigmentation in vitiligo with strong safety and outperformed JAK inhibitors.FBRX
Study result - Biotech seeks up to $500M for autoimmune drug pipeline, targeting major unmet needs.FBRX
Registration filing - Shelf registration enables up to $500M in offerings to fund autoimmune drug development.FBRX
Registration filing - FB102 won FDA Fast Track, posted $22.1M Q1 loss, and raised $172.5M to fund clinical trials.FBRX
Q1 2026 - Key votes include director elections, auditor ratification, say-on-pay, and equity plan expansion.FBRX
Proxy filing - FB102 clinical trials progress, R&D costs surge, and net loss widens amid strong cash position.FBRX
Q4 2025 - FB102 showed significant histological and symptom benefits with good safety in celiac disease.FBRX
Study Update